FDA clears at‑home neuromodulation
Regulators have started approving devices that let people do physician-directed brain stimulation at home, signaling greater comfort with home-based brain‑health tools. Two reports describe FDA clearance or approval for at‑home neuromodulation systems — named in coverage as Flow‑100 and ProlivRx — that are positioned for major depressive disorder with physician oversight. The practical effect is that home devices are becoming a mainstream option, which shifts expectations about what care families can and should receive at home. (patientcareonline.com) (psychiatrictimes.com)
Brain stimulation used to mean trips to a clinic, a technician, and a machine you could not bring home. In late 2025 and early 2026, the Food and Drug Administration signed off on two prescription systems that move part of that care into the living room under physician oversight: Flow Neuroscience’s FL-100 and Neurolief’s ProlivRx. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The basic idea is simple: a device sends a small electrical signal through nerves or brain regions linked to mood, the way a pacemaker sends timed pulses to the heart. The treatment is noninvasive, which means no surgery, and both systems are prescription devices rather than wellness gadgets sold over the counter. (accessdata.fda.gov 1) (accessdata.fda.gov 2) Flow’s FL-100 uses transcranial direct current stimulation, which is a weak current delivered through electrodes on the scalp. Its Food and Drug Administration indication covers adults 18 and older with moderate to severe major depressive disorder in the current episode, either by itself or alongside other treatment, as long as they are not considered medication-refractory. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The company says the headset targets the dorsolateral prefrontal cortex, a frontal brain region involved in planning, attention, and mood regulation. In practical terms, that is a way of trying to nudge activity in circuits that often look disrupted during depression. (psychiatrictimes.com) (patientcareonline.com) Neurolief’s ProlivRx uses a different route. It is a cranial electrotherapy stimulator that delivers focal, multi-channel stimulation through occipital and trigeminal nerve pathways, which means it works through nerves at the back of the head and face that feed signals into brain networks tied to mood. (accessdata.fda.gov) (psychiatrictimes.com) Its label is narrower than Flow’s. ProlivRx is approved as an adjunctive treatment for adults whose major depressive disorder did not improve enough with antidepressants, so it is positioned as a next-step option after at least one medication has already fallen short. (psychiatrictimes.com) (hcplive.com) The regulatory path also tells you how seriously the agency is treating these products. Flow’s FL-100 went through the premarket approval process with a published Summary of Safety and Effectiveness Data, and ProlivRx appears in the Food and Drug Administration premarket approval database as PMA P250010. (accessdata.fda.gov) (accessdata.fda.gov) That matters because home treatment is not the same as unsupervised treatment. Flow’s instructions say the device is for people diagnosed with major depressive disorder who are receiving treatment by a medical provider, and the labeling flags extra caution for pregnancy, suicidal thoughts, and implanted devices such as pacemakers. (accessdata.fda.gov) The shift here is less about one headset beating another and more about where care happens. For years, neuromodulation for depression usually meant clinic infrastructure; now the Food and Drug Administration is allowing physician-directed electrical treatment for some patients at home, which starts to make brain-health care look more like home sleep testing or home dialysis than a hospital-only procedure. (accessdata.fda.gov) (accessdata.fda.gov) The next test is not whether these devices can clear regulators, because they already did. The next test is whether insurers, health systems, and psychiatrists treat home neuromodulation as routine enough that a patient with depression can get a prescription device in 2026 without first fighting through the old clinic-only bottleneck. (patientcareonline.com) (prnewswire.com)
